MX2020004513A - Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. - Google Patents

Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.

Info

Publication number
MX2020004513A
MX2020004513A MX2020004513A MX2020004513A MX2020004513A MX 2020004513 A MX2020004513 A MX 2020004513A MX 2020004513 A MX2020004513 A MX 2020004513A MX 2020004513 A MX2020004513 A MX 2020004513A MX 2020004513 A MX2020004513 A MX 2020004513A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical compositions
cocrystals
treatment involving
involving same
Prior art date
Application number
MX2020004513A
Other languages
English (en)
Inventor
Benjamin S Lane
Chong-Hui Gu
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2020004513A publication Critical patent/MX2020004513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan formas sólidas de un compuesto útil para tratar el cáncer, composiciones farmacéuticas del mismo y métodos para tratar el cáncer que comprenden administrar las formas sólidas descritas en la presente descripción a un paciente que lo necesita.
MX2020004513A 2017-11-02 2018-11-02 Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. MX2020004513A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Publications (1)

Publication Number Publication Date
MX2020004513A true MX2020004513A (es) 2020-09-17

Family

ID=64572453

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004513A MX2020004513A (es) 2017-11-02 2018-11-02 Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MX2022014792A MX2022014792A (es) 2017-11-02 2020-07-13 Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014792A MX2022014792A (es) 2017-11-02 2020-07-13 Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.

Country Status (17)

Country Link
US (2) US11345677B2 (es)
EP (1) EP3704101A1 (es)
JP (2) JP7335877B2 (es)
KR (1) KR20200095480A (es)
CN (1) CN111527076B (es)
AU (2) AU2018360827B2 (es)
BR (1) BR112020008598A2 (es)
CA (1) CA3081535A1 (es)
EA (1) EA202091112A1 (es)
IL (2) IL305426B1 (es)
MA (1) MA50526A (es)
MX (2) MX2020004513A (es)
PH (1) PH12020550462A1 (es)
SG (1) SG11202003612VA (es)
TW (1) TWI796377B (es)
UA (1) UA127380C2 (es)
WO (1) WO2019090059A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
WO2022036033A2 (en) 2020-08-12 2022-02-17 Servier Pharmaceuticals, Llc Solid state forms of an organic compound
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061299A1 (en) * 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US9579324B2 (en) * 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
JP2021501766A (ja) 2021-01-21
US11345677B2 (en) 2022-05-31
MA50526A (fr) 2020-09-09
TW201930285A (zh) 2019-08-01
AU2018360827A1 (en) 2020-05-14
CN111527076A (zh) 2020-08-11
US20210198234A1 (en) 2021-07-01
TWI796377B (zh) 2023-03-21
US11851417B2 (en) 2023-12-26
AU2024203186A1 (en) 2024-05-30
CN111527076B (zh) 2024-03-12
IL274123B2 (en) 2024-01-01
UA127380C2 (uk) 2023-08-02
TW202337885A (zh) 2023-10-01
IL274123A (en) 2020-06-30
MX2022014792A (es) 2023-01-16
EP3704101A1 (en) 2020-09-09
CA3081535A1 (en) 2019-05-09
JP7335877B2 (ja) 2023-08-30
IL305426A (en) 2023-10-01
BR112020008598A2 (pt) 2021-01-26
US20220363661A1 (en) 2022-11-17
WO2019090059A1 (en) 2019-05-09
IL274123B1 (en) 2023-09-01
PH12020550462A1 (en) 2021-03-22
SG11202003612VA (en) 2020-05-28
JP2023093666A (ja) 2023-07-04
AU2018360827B2 (en) 2024-02-22
KR20200095480A (ko) 2020-08-10
EA202091112A1 (ru) 2020-07-23
JP7499377B2 (ja) 2024-06-13
IL305426B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.